foxo4 dri peptide senolytic 2023 inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis FOX04-DRI - Apollo Peptide Sciences

However, there is a solution for growth hormone deficiency-related aging

Food & Drug Administration (FDA) announced it will convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23 and 24, 2026, to discuss permitting compounding pharmacies to prepare certain peptides used for ulcerative colitis (UC), wound healing, obesity, insomnia, opioid withdrawal, inflammatory conditions, and osteoporosis, among other conditions

Latvala, S., Jacobsen, B., Otteneder, M

And the infrastructure that would normally answer that question, large pharmaceutical trials with thousands of patients and independent oversight, does not exist for this compound and shows no signs of materializing